End of an era looming for the ASX

Published 19-APR-2016 09:45 A.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

The Australian Stock Exchange (ASX) may soon lose its monopoly on clearing Australian stock market transactions, if ASIC approves new proposals from rival clearing house Chi-X.

Chi-X Australia proposes to liberalise existing clearing rules that force all transactions to be cleared via the ASX. If Chi-X’s plans are approved, the clearer could save investors around 20% on transactions costs when buying and selling Australian shares, as well as open the door to new financial products that could benefit investors.

At the present time, Chi-X Australia generates around A$40 million per year in revenue for the ASX as clearing fees. The fact that it has no alternative clearer has riled Chi-X John Fildes and led to criticisms that the ASX is abusing its market position.

Chi-X CEO Mr. John Fildes

Chi-X CEO John Fildes said Chi-X “would produce cheaper post-trade services and make it easier for new products to be rolled out” in an interview with The Herald Sun’s ‘Business Daily’ publication.

One example of such a financial product is TRaCRs – a financial product enabling Australian investors to gain exposure to US-listed stocks such as Coca-Cola, Google and Apple. Effectively, TRaCRs replicate American Depositary Receipts (ADRs) in allowing companies to have their stock available for purchase in other countries.

If ASIC approves of the plans, Chi-X wants to offer these products later this year.

“We are confident TraCRs will be a great vehicle for Australian SMSF [self-managed superannuation funds] and other retail investors looking to diversify their portfolios,” said Mr. Fildes.

In recent months, Mr. Fildes has often criticised the ASX for not providing fair and equal access to its clearing house because of its monopoly status. Currently, the ASX is the only organisation permitted to run a clearing house, conducting the transfer of money for scrip between buyers and sellers.

Chi-X claims that numerous rules and restrictions for other market participants have made it difficult for other entities to compete thereby creating an unfair playing field. Another criticism levied at the ASX by Chi-X is that its ability to increase clearing fees has hampered Chi-X from developing new investment products such as TRaCRs.

Stateside investing

Investing in the US stock market is not a novel idea for Australian capital markets.

The ASX has made previous attempts to allow Australian investors access to US equities but its plans stalled at the approval stage with the Australian Securities and Investment Commission (ASIC). In 2012, the ASX proposed to launch unsponsored depository receipts (UDRs) offering offshore stocks to Australian-based investors; but was denied by ASIC on the grounds of widely different disclosure obligations and reporting requirements between Australia and the US.

Brendan Wills and John Fildes, CEO of Chi-X

Mr. Fildes says that Chi-X has been given the “verbal green light by ASIC to move ahead with TRaCRs” because ASIC’s prior concerns regarding disclosure had been resolved in early discussions.

“We will be providing a new website with continuous disclosure that is as good, if not better, than what investors get in the US,” Mr Fildes said. Issuers of TRaCRs could be exempt from continuous disclosure obligations, on the grounds that the stocks are publicly traded in the US and Chi-X will set up a separate website, which will provide continuous disclosure of price-sensitive information.

According to Mr. Fildes, Chi-X has spent a “seven-figure sum” on TRaCRs and numerous other new products in the process of being launched including warrants, exchange tradeable funds, new trading indices and “quoted-managed funds”, due in June, he said.

More about Chi-X Australia

Chi-X Australia became profitable in 2015 after operating in Australia since 2011.

In September last year brokers OpenMarkets, Shaw and Partners and Morgans joined the Chi-X ­market, taking the number of Chi-X participants to 37 since October 2011.

In December 2015, Chi-X Global sold its Canadian business unit to US market operator Nasdaq for an undisclosed sum.

In January 2016, Chi-X’s Australian, Hong Kong and Japan businesses were sold to US private equity firm JC Flowers & Co.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X